Literature DB >> 8233054

Localization of rat brain binding sites for [3H]tomoxetine, an enantiomerically pure ligand for norepinephrine reuptake sites.

D R Gehlert1, S L Gackenheimer, D W Robertson.   

Abstract

The distribution of binding sites for the potent inhibitor of norepinephrine (NE) reuptake, [3H]tomoxetine, was examined in rat brain using quantitative autoradiography. Scatchard analysis of [3H]tomoxetine-binding to slide-mounted sections of rat forebrain indicated that the ligand bound to two sites, a high-affinity site with a Kd of 0.29 nM and a lower-affinity site with a Kd of 16 nM. Pharmacological characterization of this high-affinity site was consistent with labelling a NE-uptake site in brain. Autoradiographic localization of the binding sites for [3H]tomoxetine was performed at a ligand concentration of 1 nM representing the distribution of high-affinity sites. The radioligand bound with a distribution of binding sites that was consistent with the known distribution of NE-containing neurons. The highest levels of binding were seen in regions, such as the locus coeruleus, bed nucleus of the stria terminalis, anterior ventral nucleus of the thalamus and the paraventricular nucleus of the hypothalamus. Low levels were seen in regions such as the caudate-putamen, ventral tegmental area and zona reticulata of the substantia nigra, where NE-containing neurons have been reported to be low. Binding to all these sites was inhibited by 1 microM desipramine which produced autoradiograms with a uniform nonspecific binding. These results indicate that low concentrations of [3H]tomoxetine can be used to localize and characterize NE-binding sites. Further study will be necessary to determine the nature of the low-affinity binding site.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8233054     DOI: 10.1016/0304-3940(93)90737-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  19 in total

1.  Atomoxetine, Parent Training, and Their Combination in Children With Autism Spectrum Disorder and Attention-Deficit/Hyperactivity Disorder.

Authors:  Benjamin L Handen; Michael G Aman; L Eugene Arnold; Susan L Hyman; Rameshwari V Tumuluru; Luc Lecavalier; Patricia Corbett-Dick; Xueliang Pan; Jill A Hollway; Kristin A Buchan-Page; Laura B Silverman; Nicole V Brown; Robert R Rice; Jessica Hellings; Daniel W Mruzek; Sarah McAuliffe-Bellin; Elizabeth A Hurt; Melissa M Ryan; Lynne Levato; Tristram Smith
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2015-09-03       Impact factor: 8.829

Review 2.  Genetic Influence on Efficacy of Pharmacotherapy for Pediatric Attention-Deficit/Hyperactivity Disorder: Overview and Current Status of Research.

Authors:  Nada A Elsayed; Kaila M Yamamoto; Tanya E Froehlich
Journal:  CNS Drugs       Date:  2020-04       Impact factor: 5.749

3.  Atomoxetine-induced increases in monoamine release in the prefrontal cortex are similar in spontaneously hypertensive rats and Wistar-Kyoto rats.

Authors:  Yukio Ago; Masato Umehara; Kosuke Higashino; Shigeru Hasebe; Kazumi Fujita; Kazuhiro Takuma; Toshio Matsuda
Journal:  Neurochem Res       Date:  2014-03-15       Impact factor: 3.996

4.  Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.

Authors:  Nicholas Seneca; Balázs Gulyás; Andrea Varrone; Magnus Schou; Anu Airaksinen; Johannes Tauscher; Francois Vandenhende; William Kielbasa; Lars Farde; Robert B Innis; Christer Halldin
Journal:  Psychopharmacology (Berl)       Date:  2006-08-04       Impact factor: 4.530

5.  Correlation of increased grooming behavior and motor activity with alterations in nigrostriatal and mesolimbic catecholamines after alpha-melanotropin and neuropeptide glutamine-isoleucine injection in the rat ventral tegmental area.

Authors:  M S Sánchez; M Barontini; I Armando; M E Celis
Journal:  Cell Mol Neurobiol       Date:  2001-10       Impact factor: 5.046

Review 6.  Spotlight on atomoxetine in adults with attention-deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 7.  Non-stimulant medications in the treatment of ADHD.

Authors:  Tobias Banaschewski; Veit Roessner; Ralf W Dittmann; Paramala Janardhanan Santosh; Aribert Rothenberger
Journal:  Eur Child Adolesc Psychiatry       Date:  2004       Impact factor: 4.785

Review 8.  Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents.

Authors:  Karly P Garnock-Jones; Gillian M Keating
Journal:  Paediatr Drugs       Date:  2009       Impact factor: 3.022

Review 9.  Atomoxetine.

Authors:  Dene Simpson; Caroline M Perry
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder.

Authors:  Dene Simpson; Greg L Plosker
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.